GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lobe Sciences Ltd (XCNQ:LOBE) » Definitions » EV-to-EBIT

Lobe Sciences (XCNQ:LOBE) EV-to-EBIT : -2.11 (As of Dec. 16, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Lobe Sciences EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Lobe Sciences's Enterprise Value is C$5.62 Mil. Lobe Sciences's EBIT for the trailing twelve months (TTM) ended in May. 2024 was C$-2.67 Mil. Therefore, Lobe Sciences's EV-to-EBIT for today is -2.11.

The historical rank and industry rank for Lobe Sciences's EV-to-EBIT or its related term are showing as below:

XCNQ:LOBE' s EV-to-EBIT Range Over the Past 10 Years
Min: -11.45   Med: -0.4   Max: 24.43
Current: -2.11

During the past 13 years, the highest EV-to-EBIT of Lobe Sciences was 24.43. The lowest was -11.45. And the median was -0.40.

XCNQ:LOBE's EV-to-EBIT is ranked worse than
100% of 429 companies
in the Biotechnology industry
Industry Median: 8.9 vs XCNQ:LOBE: -2.11

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Lobe Sciences's Enterprise Value for the quarter that ended in May. 2024 was C$5.62 Mil. Lobe Sciences's EBIT for the trailing twelve months (TTM) ended in May. 2024 was C$-2.67 Mil. Lobe Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in May. 2024 was -47.46%.


Lobe Sciences EV-to-EBIT Historical Data

The historical data trend for Lobe Sciences's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lobe Sciences EV-to-EBIT Chart

Lobe Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Aug19 Aug20 Aug21 Aug22 Aug23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -12.37 -3.75 -1.13 -0.22 -0.49

Lobe Sciences Quarterly Data
Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.37 -0.49 -0.76 -0.76 -2.11

Competitive Comparison of Lobe Sciences's EV-to-EBIT

For the Biotechnology subindustry, Lobe Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lobe Sciences's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lobe Sciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Lobe Sciences's EV-to-EBIT falls into.



Lobe Sciences EV-to-EBIT Calculation

Lobe Sciences's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=5.615/-2.665
=-2.11

Lobe Sciences's current Enterprise Value is C$5.62 Mil.
Lobe Sciences's EBIT for the trailing twelve months (TTM) ended in May. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-2.67 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lobe Sciences  (XCNQ:LOBE) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Lobe Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in May. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: May. 2024 ) =EBIT / Enterprise Value (Q: May. 2024 )
=-2.665/5.6152
=-47.46 %

Lobe Sciences's Enterprise Value for the quarter that ended in May. 2024 was C$5.62 Mil.
Lobe Sciences's EBIT for the trailing twelve months (TTM) ended in May. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-2.67 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lobe Sciences EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Lobe Sciences's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Lobe Sciences Business Description

Traded in Other Exchanges
Address
1199 West Hastings Street, Suite 1400, Vancouver, BC, CAN, V6E 3T5
Lobe Sciences Ltd is a biopharmaceutical company committed to discovering and developing patient-focused medicines for orphan and rare diseases. It is engaged in drug research and development to improve brain and mental health and wellness. The company plans to commercialize a medical food named Altemia for the treatment of Sickle Cell Disease and has other drugs in pipeline such as L-130 Treatment for Chronic Cluster Headache, L-131 Treatment for Pediatric Anxiety and S-100 Treatment for Sickle Cell Disease.

Lobe Sciences Headlines

No Headlines